Short interest for Zoetis gives investors a sense of the degree to which investors are betting on the decline of Zoetis's stock. Short interest data is updated every two weeks.

Zoetis Stock (NYSE:ZTS), Short Interest Report

Zoetis

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Wall Street US stocks

Earnings

Earnings Beats

Earnings Misses

Equities

Large Cap

Macro Economic Events

Market Summary

Broad U.S. Equity ETFs

Commodities

Economics

Federal Reserve

Movers

ETFs

$BTC

AAPL

AMGN

BKNG

COIN

DASH

SPDR Dow Jones Industrial Average ETF Trust

FTNT

MELI

MNST

MRNA

QCOM

REGN

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

U.S. stock markets surged during Thursday’s midday trading session in New York, with major averages all showing gains.

Wall Street Inches Up After Powell&#39;s Inflation Remarks; Chipmakers Rebound; Gold, Crude Falter: What&#39;s Driving Markets Thursday?

News

Guidance

PAWZ

Zoetis Inc (NYSE: ZTS) beats revenue expectations with 10% Y/Y increase. U.S. segment up 16%, international up 3%. FY24 guidance revised higher. ZTS shares up 4.66%. 

Why Animal Health-Focused Zoetis Shares Are Trading Higher Today

Wall Street

Futures

Previews

Pre-Market Outlook

Markets

Trading Ideas

AMZN

BBAI

BJRI

CHRW

CYBR

DKNG

EBAY

ETSY

EXPE

FIVN

FRSH

FSLR

ILMN

KLIC

MPWR

NOVA

NTGR

OPEN

PENN

QRVO

RACE

UPWK

WOLF

U.S. stocks look to push ahead on a positive path, now that the Federal Reserve’s rate decision is in the rearview mirror. Major index futures point to a positive open on Thursday.

Nasdaq, S&amp;P 500 Futures Rise Ahead Of Apple Earnings: Why This Analyst Thinks &#39;No Cut&#39; Scenario May Not Be Negative For Market

Zoetis Inc

Ztest Electronics Inc

U.S. stock markets surged during Thursday&#8217;s midday trading session in New York, with major averages all showing gains.
Trader sentiment rebounded thanks to positive signals from corporate earnings and relief after Fed Chair Jerome Powell dismissed the possibility of a rate hike <a href="https://www.benzinga.com/economics/macro-economic-events/24/05/38584705/federal-reserve-takes-cautious-stand-on-inflation-powell-signals-preference-for-r">during Wednesday&#8217;s press conference.</a>
The S&amp;P 500 inched 0.3% up at 12:30 p.m. ET, while the tech-heavy Nasdaq 100 slightly outperformed, up 0.6%. Semiconductors stood out as a bright spot, buoyed by <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38588728/5-qualcomm-analysts-highlight-q2-results-q3-guidance-solid-beat-and-raise-amid-carn">robust quarterly results and optimistic guidance</a> from Qualcomm Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>). The iShares Semiconductor ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NYSE">SOXX</a>) rose 1.2%, after plummeting 3.4% Wednesday. 
Small caps fared better than large caps, with the iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) up 1%. 
Treasury yields moved slightly lower after Wednesday&#8217;s Federal Open Market Committee (FOMC) meeting indicating reduced fears on potential upward moves in interest rates. The policy-sensitive 2-year yield fell to 4.9%, after touching 5.05% on Wednesday. 
Commodities slid, with gold dropping by 0.8% and West Texas Intermediate (WTI) light crude declining by 0.5% to $78 a barrel, poised to close at its lowest level since Mar. 13, 2024.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) slightly rebounded to $59,000 after tumbling to as low as $56,500 Wednesday. 
<h1 class="wp-block-heading">Thursday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,000.82</td>
<td>1.0%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>17,396.76</td>
<td>0.6%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>37,994.03</td>
<td>0.3%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,028.09</td>
<td>0.3%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:37 p.m. EDT</figcaption></figure>
The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.4% to $502.18, the&nbsp;SPDR Dow Jones Industrial Average (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) rose 0.4% to $380.46 and the tech-heavy&nbsp;Invesco QQQ Trust&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rocketed 0.6% to $424.21, according to&nbsp;<a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.&nbsp;
Sector-wise, the Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) outperformed, up 0.7%, followed by the Consumer Staples Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>), up 0.6%. The Materials Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>) was the major laggard, down 1%.
<h1 class="wp-block-heading">Thursday&#8217;s Stock Movers</h1>
<ul>
<li>Linde plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIN#NASDAQ">LIN</a>) fell 5.8% after the company missed quarterly revenue estimates. </li>
<li>Other stocks reacting to earnings were ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>) down 1.6%, Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) up 3.8%, Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) down 2.4%, Southern Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SO#NYSE">SO</a>) up 0.6%, Zoetis Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) up 6%, Moodys Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCO#NYSE">MCO</a>) down 1%, Apollo Global Management Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) up 3.9%, Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) up 9%, American International Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>) up 1.9%, MetLife Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>) down 4% and DoorDash Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>). </li>
<li>Notable companies reporting after the close include Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), Booking Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>), EOG Resources Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EOG#NYSE">EOG</a>), MercadoLibre Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>), Pioneer Natural Resource Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PXD#NYSE">PXD</a>), Monster Beverage Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNST#NASDAQ">MNST</a>), Coinbase Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) and Fortinet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>). </li>
</ul>
Read Now: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38590992/sell-in-may-and-go-away-does-the-trading-strategy-hold-up-in-election-years">Sell In May And Go Away: Does The Trading Strategy Hold Up In Election Years?</a>
Photo: Shutterstock

Wall Street Inches Up After Powell's Inflation Remarks; Chipmakers Rebound; Gold, Crude Falter: What's Driving Markets Thursday?

Analyst Ratings

Live On CNBC, Zoetis CEO Kristin Peck Discusses Company Earnings, Demand

Zoetis Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) shares are trading higher after the company reported first-quarter FY24 revenue of $2.19 billion, up 10% Y/Y on reported and 12% Y/Y on an operational basis,&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/05/b38577408/zoetis-announces-first-quarter-2024-results" rel="noreferrer noopener">beating the&nbsp;consensus of $2.132 billion</a>.
Revenue in the U.S. segment was $1.2 billion, up 16% Y/Y.&nbsp;Sales of companion animal products increased by 25%, driven by growth in&nbsp;key&nbsp;franchises&nbsp;including&nbsp;Simparica Trio, flea, tick&nbsp;and&nbsp;heartworm combination&nbsp;product,&nbsp;key&nbsp;dermatology portfolio, including Apoquel&nbsp;and Cytopoint, and&nbsp;osteoarthritis (OA) pain products, Librela&nbsp;for dogs and Solensia&nbsp;for cats.
Revenue in the&nbsp;International segment&nbsp;stood at $1.0 billion, rising by 3%&nbsp;on a reported basis and by 8% Y/Y operationally in the quarter.
Net income for the first quarter was $599 million, or $1.31 per diluted share, an increase of 9% and 10%, respectively,&nbsp;on a reported basis.
Adjusted net income for the first quarter was $634 million, or $1.38 per share, an increase of 4% and 5%, respectively, on a reported and rising 15%&nbsp;and 17% on an operational basis,&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">beating the consensus of $1.34</a>.
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/news/large-cap/24/03/37967535/largest-animal-health-firm-zoetis-hit-with-european-probe-over-possible-breach-of-competition-rule" rel="noreferrer noopener">Largest Animal Health Firm Zoetis Hit With European Probe Over Possible Breach of Competition Rules Related To Dog Pain Medicine</a>
FY24 Guidance Revised:&nbsp;Zoetis updated FY24 revenue guidance to $9.050 billion to $9.200 billion (from $9.075 billion-$9.225 billion), representing an operational growth of 8.5% to 10.5%, vs. the consensus of $9.16 billion.
The animal health-focused Zoetis now sees FY24 adjusted EPS of $5.71 to $5.81 (<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/02/37102045/animal-health-focused-zoetis-stock-faces-near-term-pressure-analyst-cites-uncertain" rel="noreferrer noopener">from $5.74-$5.84 earlier) vs. the consensus of $5.79.</a>
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38223218/animal-health-giant-zoetis-stock-crumbles-possible-side-effect-of-its-pet-arthritis-pain-drugs-si" rel="noreferrer noopener">Animal Health Giant Zoetis Stock Crumbles: Possible Side Effect Of Its Pet Arthritis Pain Drugs Sickened Dogs, Cats</a>
Investors&nbsp;can gain exposure to the stock via&nbsp;ProShares Pet Care ETF&nbsp;(BATS:<a class="ticker" href="https://www.benzinga.com/stock/PAWZ#BATS">PAWZ</a>) and&nbsp;VanEck Agribusiness ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOO#NYSE">MOO</a>).
Price Action: ZTS shares are up 5.21% at $166.76 at the last check Thursday.
Image by Africa Studio via Shutterstock

WIIM

Zoetis shares are trading higher after the company reported better-than-expected Q1 financial results.

Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) reported quarterly earnings of $1.38 per share which beat the analyst consensus estimate of $1.34 by 2.99 percent. This is a 5.34 percent increase over earnings of $1.31 per share from the same period last year. The company reported quarterly sales of $2.190 billion which beat the analyst consensus estimate of $2.132 billion by 2.70 percent. This is a 9.50 percent increase over sales of $2.000 billion the same period last year.

Zoetis Q1 2024 Adj EPS $1.38 Beats $1.34 Estimate, Sales $2.190B Beat $2.132B Estimate

U.S. stocks look to push ahead on a positive path, now that the <a href="https://www.benzinga.com/markets/equities/24/05/38563545/powell-keeps-hawks-at-bay-says-interest-rate-hike-unlikely-stocks-gold-rally-while-treasury-yiel">Federal Reserve&#8217;s rate decision </a>is in the rearview mirror. Major index futures point to a positive open on Thursday. Pent-up demand following the recent losses could provide some upward thrust to the market but a lot would ride on the earnings reports that traders get to digest.
Apple, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) is on track to report after the market closes, while most tech earnings released after Wednesday&#8217;s closing bell have triggered negative reactions. Traders may also watch out for the jobless claims data and bond yields, given their significance for the Fed funds rate.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Performance (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>+0.95%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>+0.64%</td>
</tr>
<tr>
<td>Dow</td>
<td>+0.36%</td>
</tr>
<tr>
<td>R2K</td>
<td>+0.87%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption"> In <a href="https://www.benzinga.com/premarket/" target="_blank" rel="noreferrer noopener">premarket</a>&nbsp;trading on Thursday, the&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) climbed 0.67% to $503.71,&nbsp;and the&nbsp;Invesco QQQ ETF&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) jumped 0.97% to $425.62, according to&nbsp;<a href="https://benzinga.grsm.io/lxquj26b2sag" target="_blank" rel="noreferrer noopener">Benzinga Pro data</a>.</figcaption></figure>
Cues From Previous Session:
Despite Fed Chair Jerome Powell treading a dovish line, the major averages closed mixed on Wednesday. Stocks mostly languished sideways until the afternoon, characteristic of a Fed decision day. They began to rise after the pause verdict was announced and the upward momentum accelerated after Powell&#8217;s press conference.
The Fed chief made it clear that the Fed would likely ease rather than tighten further and also conceded that the monetary policy is restrictive. Sentiment reversed course in the last thirty minutes of trading and the averages reversed course before closing mixed.
The S&amp;P 500 and the Nasdaq Composite fell for a second straight session, returning to their lowest closing level since April 22. The Dow Industrials ended higher, thanks to strong gains in the shares of Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) and Amazon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>). Energy and IT stocks fell sharply, while utility and communication services stocks gained ground.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-0.33%</td>
<td>15,605.48</td>
</tr>
<tr>
<td>S&amp;P 500 Index</td>
<td>-0.34%</td>
<td>5,018.39</td>
</tr>
<tr>
<td>Dow Industrials</td>
<td>+0.23%</td>
<td>37,903.29</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>+0.32%</td>
<td>1,980.23</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
There is more downside risk to the market in the intermediate term, said Morgan Stanley&#8217;s Lisa Shalett. She noted that the prospect of interest rate cuts helped buoy stocks in the first quarter. The strength continued, thanks to decent first-quarter 2024 company earnings results thus far as well as investors' hope that above-trend economic growth could offset any negative effects from higher rates. 
The odds of the more concerning recessionary &#8220;hard landing,&#8221; in which the economy slows sharply, have jumped to about 25%-30%, she said.&nbsp;
Larry Tentarelli, Chief Technical Strategist, Blue Chip Daily Trend Report, said a &#8220;no cut scenario&#8221; in 2024 may not be a negative, as long as inflation does not turn up and the economy holds up reasonably well.
&#8220;We believe that the Fed will remain data dependent, meeting to meeting. Unless 12-month core PCE starts to drop meaningfully, to at least 2.40% or less in the next two months than any rate cuts could be delayed, including for all of 2024,&#8221; he said.
&#8220;A caveat here would be the labor market and if jobs start to weaken notably. A very weak jobs market could prompt the Fed to cut, but this is not the case now, with a very strong labor market.&#8221;
Upcoming Economic Data:
<ul>
<li>The Labor Department is due to release its jobless claims report at 8:30 a.m. EDT, with economists, on average, expecting the number of individuals filing for unemployment benefits to come in at 212,000 in the week ended April 25. This compares to the previous reporting week&#8217;s 207,000.</li>
<li>The Labor Department will also release its preliminary first-quarter productivity and costs report around the same time. The consensus estimates call for a 0.5% quarter-over-quarter increase in non-farm productivity and a 4% increase in unit labor costs. This compares to 3.2% and 0.4% growth rates, respectively, for the fourth quarter.</li>
<li>The Commerce Department is scheduled to release its trade balance and factory goods orders data, both for March, at 8:30 a.m. EDT and 10 a.m. EDT, respectively. The trade deficit may have widened to $69.5 billion, up from a deficit of $68.9 billion in February. Factory orders may have increased 1.7% month-over-month, faster than the 1.4% growth in February.</li>
<li>The Treasury will auction four- and eight-week bills at 11:30 a.m. EDT.</li>
</ul>
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How To Trade Futures </a>
Stocks In Focus: 
<ul>
<li>Shares of freight &amp; logistics company C.H. Robinson Worldwide, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRW#NASDAQ">CHRW</a>) climbed over 12% <a href="https://www.benzinga.com/premarket">in premarket trading</a> following its quarterly results.</li>
<li>Other shares moving on earnings news are eBay Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EBAY#NASDAQ">EBAY</a>) (down over 3%), Etsy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETSY#NASDAQ">ETSY</a>) (down over 12.50%), First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) (down about 2.50%), Freshworks Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSH#NASDAQ">FRSH</a>) (down over 27%), Kulicke and Soffa Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLIC#NASDAQ">KLIC</a>) (down about 4%), MGM Resorts International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGM#NYSE">MGM</a>) (up over 6%), NETGEAR, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTGR#NASDAQ">NTGR</a>) (down over 20%), Monolithic Power Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>) (up over 4%), Qorvo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRVO#NASDAQ">QRVO</a>) (down over 10%), Sunnova Energy International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) (up over 3.50%), Upwork Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPWK#NASDAQ">UPWK</a>) (up about 10%), Wolfspeed, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) (down about 9%), DoorDash, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) (down over 12%) and Zillow Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZG#NASDAQ">ZG</a>) (down over 6%).</li>
<li>ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>), CyberArk Software Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYBR#NASDAQ">CYBR</a>), Ferrari N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RACE#NYSE">RACE</a>), Intercontinental Exchange, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ICE#NYSE">ICE</a>), Kimco Realty Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KIM#NYSE">KIM</a>), Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), PENN Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PENN#NASDAQ">PENN</a>), Wayfair Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>) and Zoetis Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) are among the <a href="https://www.benzinga.com/calendars/earnings">notable companies reporting earnings ahead of the market opening.</a></li>
<li>Notable names reporting after the close are Amgen, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), Apple, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) BigBear.ai Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAI#NYSE">BBAI</a>), BJ&#8217;s Restaurants, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJRI#NASDAQ">BJRI</a>), Booking Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>), Cloudflare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>), Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>), Consolidated Edison, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ED#NYSE">ED</a>), DraftKings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>), Five9, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVN#NASDAQ">FIVN</a>), Expedia Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>), Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), Live Nation Entertainment, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>), United States Steel Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>), Regency Centers Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REG#NASDAQ">REG</a>), Reinsurance Group of America, Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RGA#NYSE">RGA</a>), Pioneer Natural Resources Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PXD#NYSE">PXD</a>), Opendoor Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPEN#NASDAQ">OPEN</a>) and Monster Beverage Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNST#NASDAQ">MNST</a>).</li>
</ul>
Commodities, Bonds, and Global Equity Markets:
Crude oil futures, which slumped over 3.50% Wednesday following the Fed decision, recovered slightly on Thursday but held below the $80 psychological resistance. After advancing modestly on Wednesday, gold futures reversed course, with an ounce of the yellow metal fetching $2,307.45.
After Wednesday&#8217;s retreat, the 10-year note yield edged up and was around the 4.62% mark.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) fell below $60,000 but saw a modest recovery early in U.S. premarket hours.
Asian markets, which reopened after Wednesday&#8217;s Labor Day holiday, ended mostly higher, led by the Hong Kong market. The Chinese market remained closed for a second day, in observance of Labor Day. European stocks pulled back in early trading, with the Euros STOXX 50 Index down over 0.40%.
Read Next:<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38573665/bitcoin-selloff-just-getting-started-gold-bull-peter-schiff-spots-bearish-technical"> Bitcoin Selloff Just Getting Started? Gold Bull Peter Schiff Spots Bearish Technical Pattern As BTC Drops Below $60K</a>
Photo via Shutterstock.

Nasdaq, S&P 500 Futures Rise Ahead Of Apple Earnings: Why This Analyst Thinks 'No Cut' Scenario May Not Be Negative For Market

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$800.00</td>
<td>$35.4K</td>
<td>1.4K</td>
<td>1.4K</td>
</tr>
<tr>
<td>THC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$95.00</td>
<td>$27.5K</td>
<td>2.9K</td>
<td>1.0K</td>
</tr>
<tr>
<td>SNDL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/19/24</td>
<td>$2.50</td>
<td>$31.3K</td>
<td>7.6K</td>
<td>942</td>
</tr>
<tr>
<td>PFE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/10/24</td>
<td>$25.00</td>
<td>$34.7K</td>
<td>44.8K</td>
<td>912</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/19/24</td>
<td>$430.00</td>
<td>$66.9K</td>
<td>58</td>
<td>181</td>
</tr>
<tr>
<td>ZTS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$160.00</td>
<td>$27.6K</td>
<td>807</td>
<td>66</td>
</tr>
<tr>
<td>SYK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>05/17/24</td>
<td>$340.00</td>
<td>$96.2K</td>
<td>732</td>
<td>64</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$850.00</td>
<td>$37.4K</td>
<td>2.1K</td>
<td>56</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$450.00</td>
<td>$36.9K</td>
<td>876</td>
<td>12</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$65.00</td>
<td>$43.6K</td>
<td>38</td>
<td>10</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a call option trade that happens to be bearish, expiring in 17 day(s) on May 17, 2024. This event was a transfer of 30 contract(s) at a $800.00 strike. The total cost received by the writing party (or parties) was $35.4K, with a price of $1180.0 per contract. There were 1434 open contracts at this strike prior to today, and today 1446 contract(s) were bought and sold. 
• Regarding THC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>), we observe a call option trade with bearish sentiment. It expires in 17 day(s) on May 17, 2024. Parties traded 17 contract(s) at a $95.00 strike. The total cost received by the writing party (or parties) was $27.5K, with a price of $1620.0 per contract. There were 2959 open contracts at this strike prior to today, and today 1052 contract(s) were bought and sold. 
• Regarding SNDL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>), we observe a call option sweep with bullish sentiment. It expires in 80 day(s) on July 19, 2024. Parties traded 897 contract(s) at a $2.50 strike. This particular call needed to be split into 23 different trades to become filled. The total cost received by the writing party (or parties) was $31.3K, with a price of $35.0 per contract. There were 7602 open contracts at this strike prior to today, and today 942 contract(s) were bought and sold. 
• Regarding PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we observe a put option sweep with bearish sentiment. It expires in 10 day(s) on May 10, 2024. Parties traded 707 contract(s) at a $25.00 strike. This particular put needed to be split into 28 different trades to become filled. The total cost received by the writing party (or parties) was $34.7K, with a price of $49.0 per contract. There were 44816 open contracts at this strike prior to today, and today 912 contract(s) were bought and sold. 
• Regarding ISRG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>), we observe a call option sweep with bullish sentiment. It expires in 80 day(s) on July 19, 2024. Parties traded 181 contract(s) at a $430.00 strike. This particular call needed to be split into 33 different trades to become filled. The total cost received by the writing party (or parties) was $66.9K, with a price of $370.0 per contract. There were 58 open contracts at this strike prior to today, and today 181 contract(s) were bought and sold. 
• For ZTS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>), we notice a put option sweep that happens to be bullish, expiring in 17 day(s) on May 17, 2024. This event was a transfer of 50 contract(s) at a $160.00 strike. This particular put needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $27.6K, with a price of $550.0 per contract. There were 807 open contracts at this strike prior to today, and today 66 contract(s) were bought and sold. 
• Regarding SYK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), we observe a call option sweep with neutral sentiment. It expires in 17 day(s) on May 17, 2024. Parties traded 125 contract(s) at a $340.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $96.2K, with a price of $770.0 per contract. There were 732 open contracts at this strike prior to today, and today 64 contract(s) were bought and sold. 
• For REGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>), we notice a put option sweep that happens to be bullish, expiring in 17 day(s) on May 17, 2024. This event was a transfer of 44 contract(s) at a $850.00 strike. This particular put needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $37.4K, with a price of $850.0 per contract. There were 2130 open contracts at this strike prior to today, and today 56 contract(s) were bought and sold. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a call option trade that happens to be bullish, expiring in 17 day(s) on May 17, 2024. This event was a transfer of 10 contract(s) at a $450.00 strike. The total cost received by the writing party (or parties) was $36.9K, with a price of $3695.0 per contract. There were 876 open contracts at this strike prior to today, and today 12 contract(s) were bought and sold. 
• For VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we notice a call option trade that happens to be bullish, expiring in 199 day(s) on November 15, 2024. This event was a transfer of 17 contract(s) at a $65.00 strike. The total cost received by the writing party (or parties) was $43.6K, with a price of $2570.0 per contract. There were 38 open contracts at this strike prior to today, and today 10 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ISRG

SNDL

VKTX

10 Health Care Stocks With Whale Alerts In Today's Session

Financial giants have made a conspicuous bearish move on Zoetis. Our analysis of options history for Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) revealed 10 unusual trades.
Delving into the details, we found 30% of traders were bullish, while 70% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $101,874, and 7 were calls, valued at $355,916.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $150.0 to $185.0 for Zoetis over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Zoetis's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Zoetis's whale trades within a strike price range from $150.0 to $185.0 in the last 30 days. 
<h3>Zoetis Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1714497360_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ZTS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$10.2</td>
<td>$9.4</td>
<td>$9.4</td>
<td>$155.00</td>
<td>$151.3K</td>
<td>4.1K</td>
<td style="text-align: right;">73</td>
</tr>
<tr>
<td>ZTS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$11.9</td>
<td>$9.7</td>
<td>$9.8</td>
<td>$155.00</td>
<td>$44.1K</td>
<td>4.1K</td>
<td style="text-align: right;">63</td>
</tr>
<tr>
<td>ZTS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$29.6</td>
<td>$27.5</td>
<td>$27.5</td>
<td>$185.00</td>
<td>$44.0K</td>
<td>106</td>
<td style="text-align: right;">16</td>
</tr>
<tr>
<td>ZTS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$4.1</td>
<td>$3.7</td>
<td>$4.0</td>
<td>$165.00</td>
<td>$43.2K</td>
<td>3.3K</td>
<td style="text-align: right;">202</td>
</tr>
<tr>
<td>ZTS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$4.1</td>
<td>$3.9</td>
<td>$4.0</td>
<td>$165.00</td>
<td>$33.2K</td>
<td>3.3K</td>
<td style="text-align: right;">11</td>
</tr>
</tbody>
</table>

<h3>About Zoetis</h3>
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
<h3>Present Market Standing of Zoetis</h3>
<ul>
<li>Currently trading with a volume of 1,502,526, the ZTS's price is down by -0.33%, now at $159.17. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 2 days.</li>
</ul>
<h3>What The Experts Say On Zoetis</h3>
4 market experts have recently issued ratings for this stock, with a consensus target price of $200.0.
<ul>
<li>Maintaining their stance, an analyst from Stifel continues to hold a Buy rating for Zoetis, targeting a price of $180. </li>
<li>An analyst from Piper Sandler downgraded its action to Overweight with a price target of $195. </li>
<li>Consistent in their evaluation, an analyst from Stifel keeps a Buy rating on Zoetis with a target price of $195. </li>
<li>Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on Zoetis with a target price of $230. </li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Zoetis options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

This Is What Whales Are Betting On Zoetis

Stifel analyst Jonathan Block maintains Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) with a Buy and lowers the price target from $195 to $180.

Price Target

Stifel Maintains Buy on Zoetis, Lowers Price Target to $180

Zoetis shares are trading higher. The company announced it will sell its medicated feed additive portfolio to Phibro Animal Health for $350 million.

Corporate <a href="https://www.benzinga.com/markets/equities/24/04/38471231/strong-quarterly-earnings-fuel-market-optimism-despite-inflation-concerns-slowing-economic-growt">earnings came to the market&#8217;s rescue in the past week,</a> helping to overcome rate fears. As we look ahead to the unfolding week, it remains to be seen whether the tech earnings deluge can keep the rally&#8217;s momentum going. 
The Week That Was: High-profile Magnificent Seven earnings panned out mostly positively for the market, with Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) the outlier. The social media giant&#8217;s stock fell sharply as traders fretted over the soft second-quarter revenue guidance and the company&#8217;s massive AI investment plans. 
Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) managed to appease the Street despite the double miss as it held out the promise of an expeditious launch of a more affordable EV. 
With the earnings season now halfway through, the percentage of S&amp;P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages, <a href="https://insight.factset.com/sp-500-earnings-season-update-april-26-2024?utm_source=Direct&amp;utm_medium=Email&amp;utm_campaign=FO-04-26-2024&amp;utm_content=httpsinsightfactsetcomsp500earningsseasonupdateapril262024">said </a>FactSet in a report.
The blended first-quarter earnings growth of S&amp;P 500 companies is estimated at 3.5%, up from the 0.6% growth estimated in the week ended April 19, the financial data analytics firm said. If the trend holds, the S&amp;P 500 companies are on track to report earnings growth for the third straight quarter.
Of the 11 S&amp;P sector classes, eight sectors reported year-over-year earnings growth, led by communication services, utilities, IT, and consumer discretionary sectors. On the other hand, healthcare, energy, and materials have reported year-over-year earnings declines.
See Also: <a href="https://www.benzinga.com/money/best-tech-stocks">Best Tech Stocks Right Now</a>
Look Ahead: The unfolding week will see 175 S&amp;P 500 companies and 6 Dow 30 components releasing their quarterly scorecards. The earnings roster includes two Magnificent Seven companies, namely Apple, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) and Amazon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), e-commerce retailers, payment processors, restaurants, and energy and REIT companies.
Earnings from Apple and Amazon could be market-moving, given the weighting of these stocks in the S&amp;P 500 Index. Also, Apple is considered a bellwether, given its exposure to consumers. Morgan Stanley&#8217;s Erik Woodring expects Apple to report a slightly beat but guide June quarter revenue down. 
Investors are likely to keep a close eye on performance in China, Apple&#8217;s updated capital return framework, and capital expenditures, the analyst said.
That said, the analyst is positive on the stock ahead of its annual Worldwide Developers&#8217; Conference due on June 10th. &#8220;With Apple&#8217;s biggest WWDC event on June 10th, we&#8217;d buy post-earnings weakness,&#8221; he said.
Amazon will likely continue to report double-digit sales and profit growth in the first quarter, according to Telsey Advisory Group analyst Joseph Feldman. The analyst premised his optimism on the strength of online spending, gains from expanded merchandise and faster fulfillment, and stabilization (and growth) of AWS. 
&#8220;Importantly, we expect [a] greater focus on profits supported by the growth of higher margin categories and services, such as advertising, media, and AWS (partly helped by AI-related upgrades), the redesigned distribution network&#8230;.. and cost savings,&#8221; he said.
Notable among the <a href="https://www.benzinga.com/calendars/earnings">companies reporting earnings this week</a> are:
Monday 
<ul>
<li>Before the bell: JinkoSolar Holding Co., Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JKS#NYSE">JKS</a>), ON Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>), Koninklijke Philips N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>), SoFi Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>)</li>
<li>After the close: F5, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>), Everest Group, Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EG#NYSE">EG</a>), NXP Semiconductors N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>), Lattice Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>), MicroStrategy Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), Paramount Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>), Qiagen N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>), Rambus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBS#NASDAQ">RMBS</a>), Sanmina Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANM#NASDAQ">SANM</a>), Yum China Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUMC#NYSE">YUMC</a>)</li>
</ul>
Tuesday 
<ul>
<li>Before the bell: 3M Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>), Archer-Daniels-Midland Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>), The Coca-Cola Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>), Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), GE HealthCare Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>), McDonald&#8217;s Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>), Molson Coors Beverage Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>), PayPal Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>), Tenet Healthcare Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>)</li>
<li>After the close: Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), ONEOK, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKE#NYSE">OKE</a>), Pinterest, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>), Starbucks Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>), Skyworks Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>), Unum Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNM#NYSE">UNM</a>). Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>), Stryker Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), RenaissanceRe Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNR#NYSE">RNR</a>), Prudential Financial, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRU#NYSE">PRU</a>), Diamondback Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>), The Clorox Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>), Chesapeake Energy Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHK#NASDAQ">CHK</a>)</li>
</ul>

Wednesday 
<ul>
<li>Before the bell: Bausch + Lomb Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLCO#NYSE">BLCO</a>), CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), DuPont de Nemours, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>), The Estée Lauder Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>), Garmin Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRMN#NYSE">GRMN</a>), GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>), The Kraft Heinz Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NASDAQ">KHC</a>), KKR &amp; Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>), Logitech International S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGI#NASDAQ">LOGI</a>), Mastercard Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>), Norwegian Cruise Line Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>), Pfizer, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), Wingstop Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WING#NASDAQ">WING</a>), Yum! Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUM#NYSE">YUM</a>)</li>
<li>After the close: Albemarle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>), The Allstate Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALL#NYSE">ALL</a>), Beazer Homes USA, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BZH#NYSE">BZH</a>), C.H. Robinson Worldwide, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRW#NASDAQ">CHRW</a>), Devon Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>), eBay Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EBAY#NASDAQ">EBAY</a>), Etsy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETSY#NASDAQ">ETSY</a>), First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>), Freshworks Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSH#NASDAQ">FRSH</a>), Kulicke and Soffa Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLIC#NASDAQ">KLIC</a>), Marathon Oil Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRO#NYSE">MRO</a>), MetLife, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>), MGM Resorts International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGM#NYSE">MGM</a>), NETGEAR, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTGR#NASDAQ">NTGR</a>), Qorvo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRVO#NASDAQ">QRVO</a>), Sunnova Energy International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>), Upwork Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPWK#NASDAQ">UPWK</a>), Wolfspeed, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>), Zillow Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZG#NASDAQ">ZG</a>)</li>
</ul>
Thursday 
<ul>
<li>Before the bell: ArcelorMittal S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MT#NYSE">MT</a>), ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>), CyberArk Software Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYBR#NASDAQ">CYBR</a>), Ferrari N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RACE#NYSE">RACE</a>), Intercontinental Exchange, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ICE#NYSE">ICE</a>), Kimco Realty Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KIM#NYSE">KIM</a>), Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), PENN Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PENN#NASDAQ">PENN</a>), Wayfair Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>), Zoetis Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>)</li>
<li>After the close: Amgen, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), Apple, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), BigBear.ai Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAI#NYSE">BBAI</a>), BJ&#8217;s Restaurants, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJRI#NASDAQ">BJRI</a>), Booking Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>), Cloudflare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>), Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>), Consolidated Edison, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ED#NYSE">ED</a>), DraftKings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>), Five9, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVN#NASDAQ">FIVN</a>), Expedia Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>), Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), Live Nation Entertainment, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>), United States Steel Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>), Regency Centers Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REG#NASDAQ">REG</a>), Reinsurance Group of America, Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RGA#NYSE">RGA</a>), Pioneer Natural Resources Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PXD#NYSE">PXD</a>), Opendoor Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPEN#NASDAQ">OPEN</a>), Monster Beverage Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNST#NASDAQ">MNST</a>)</li>
</ul>
Friday 
<ul>
<li>Before the bell: American Axle &amp; Manufacturing Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXL#NYSE">AXL</a>), Cboe Global Markets, Inc. (CBOE: CBOE), Fluor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>), The Hershey Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>), Owens &amp; Minor, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>), XPO, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPO#NYSE">XPO</a>)</li>
</ul>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), an exchange-traded fund that tracks the performance of the broader S&amp;P 500 Index, ended Friday&#8217;s session up 0.95% at $508.26, according to <a href="https://benzinga.grsm.io/lxquj26b2sag">Benzinga Pro data. </a>The ETF has pulled back from its all-time high (intraday) of $524.61 hit on March 28. The Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), an ETF levered more to high-profile, non-financial tech stocks, rose 1.54% to $431.
Read Next: <a href="https://www.benzinga.com/news/earnings/earnings-misses/24/04/38464570/us-energy-stocks-fall-following-oil-giants-subdued-earnings-reports">US Energy Stocks Fall Following Oil Giants&#8217; Subdued Earnings Reports</a>

ABBV

BIIB

BLCO

CBOE

CHTR

CMCSA

FANG

FFIV

GEHC

GILD

GRMN

INTC

JBLU

JNPR

KLAC

LOGI

LRCX

LSCC

Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.zoetis.com%2F&amp;esheet=53959024&amp;newsitemid=20240428775498&amp;lan=en-US&amp;anchor=Zoetis+Inc.&amp;index=1&amp;md5=7355576a05a0142fe8a70f160d28b627">Zoetis Inc.</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) and&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pahc.com%2F&amp;esheet=53959024&amp;newsitemid=20240428775498&amp;lan=en-US&amp;anchor=Phibro+Animal+Health+Corporation&amp;index=2&amp;md5=7e2564b21339d41054b865bd66a2d964">Phibro Animal Health Corporation</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAHC#NASDAQ">PAHC</a>) today announced that they have entered into a definitive agreement where Phibro Animal Health will acquire Zoetis&#39; medicated feed additive (MFA) product portfolio, certain water soluble products and related assets for&nbsp;$350 million, subject to customary closing adjustments. This transaction is expected to be complete in the second half of calendar year 2024.
This press release features multimedia. View the full release here:

Asset Sales

PAHC

Zoetis Announced Earlier It Will Sell Its Medicated Feed Additive Portfolio To Phibro Animal Health For $350M

Financial giants have made a conspicuous bullish move on Zoetis. Our analysis of options history for Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) revealed 14 unusual trades.
Delving into the details, we found 57% of traders were bullish, while 35% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $216,721, and 11 were calls, valued at $668,978.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $140.0 to $170.0 for Zoetis over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Zoetis's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Zoetis's substantial trades, within a strike price spectrum from $140.0 to $170.0 over the preceding 30 days.
<h3>Zoetis Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1714159884_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ZTS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$4.8</td>
<td>$4.4</td>
<td>$4.4</td>
<td>$160.00</td>
<td>$220.0K</td>
<td>847</td>
<td style="text-align: right;">732</td>
</tr>
<tr>
<td>ZTS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/19/24</td>
<td>$13.5</td>
<td>$10.9</td>
<td>$11.4</td>
<td>$165.00</td>
<td>$101.4K</td>
<td>169</td>
<td style="text-align: right;">90</td>
</tr>
<tr>
<td>ZTS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/19/24</td>
<td>$3.4</td>
<td>$3.0</td>
<td>$3.2</td>
<td>$145.00</td>
<td>$83.5K</td>
<td>107</td>
<td style="text-align: right;">264</td>
</tr>
<tr>
<td>ZTS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$2.85</td>
<td>$2.8</td>
<td>$2.8</td>
<td>$165.00</td>
<td>$78.7K</td>
<td>1.1K</td>
<td style="text-align: right;">380</td>
</tr>
<tr>
<td>ZTS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$1.8</td>
<td>$1.6</td>
<td>$1.8</td>
<td>$170.00</td>
<td>$70.4K</td>
<td>833</td>
<td style="text-align: right;">431</td>
</tr>
</tbody>
</table>

<h3>About Zoetis</h3>
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Having examined the options trading patterns of Zoetis, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Zoetis's Current Market Status</h3>
<ul>
<li>Trading volume stands at 3,082,324, with ZTS's price up by 3.33%, positioned at $158.46.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 6 days.</li>
</ul>
<h3>What Analysts Are Saying About Zoetis</h3>
In the last month, 3 experts released ratings on this stock with an average target price of $206.66666666666666.
<ul>
<li>Consistent in their evaluation, an analyst from Stifel keeps a Buy rating on Zoetis with a target price of $195. </li>
<li>An analyst from Piper Sandler has revised its rating downward to Overweight, adjusting the price target to $195. </li>
<li>Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for Zoetis, targeting a price of $230. </li>
</ul>
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Zoetis with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Behind the Scenes of Zoetis's Latest Options Trends

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) in the last three months.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Zoetis, presenting an average target of $220.0, a high estimate of $260.00, and a low estimate of $195.00. Highlighting a 5.58% decrease, the current average has fallen from the previous average price target of $233.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1713888087_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of Zoetis by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Balaji Prasad</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$230.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$195.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$195.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$220.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Balaji Prasad</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$260.00</td>
<td>$255.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Zoetis. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Zoetis compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Zoetis's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Capture valuable insights into Zoetis's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ZTS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Zoetis analyst ratings.</a>
<h2>About Zoetis</h2>
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
<h3>Financial Insights: Zoetis</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Zoetis's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately 8.48%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Zoetis's net margin is impressive, surpassing industry averages. With a net margin of 23.72%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Zoetis's ROE stands out, surpassing industry averages. With an impressive ROE of 10.42%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Zoetis's ROA excels beyond industry benchmarks, reaching 3.7%. This signifies efficient management of assets and strong financial health.
Debt Management: Zoetis's debt-to-equity ratio surpasses industry norms, standing at 1.35. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Zoetis Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)

Barclays analyst Balaji Prasad maintains Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) with a Overweight and lowers the price target from $260 to $230.

Barclays Maintains Overweight on Zoetis, Lowers Price Target to $230

Six S&amp;P 500 stocks often experience a surge when shares of Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) take a dip, an analysis by CNBC revealed.
What Happened: The six U.S.-listed stocks that typically see a rise when Nvidia&#8217;s shares falter include Jack Daniel's distiller Brown-Forman Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BF#NYSE">BF</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BF#NYSE">BF</a>), gaming giant Electronic Arts Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>), health products manufacturer Henry Schein, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>), software outsourcing behemoth Cognizant Technology Solutions Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSH#NASDAQ">CTSH</a>), pet care company Zoetis Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>), and securities exchange Cboe Global Markets, Inc. (BATS:<a class="ticker" href="https://www.benzinga.com/stock/CBOE#BATS">CBOE</a>), CNBC <a href="https://www.cnbc.com/2024/04/19/here-are-the-6-stocks-that-rise-when-nvidia-shares-fall.html">reported</a> on Thursday.
The Pearson correlation coefficient, a measure of linear correlation between two variables, was used in the analysis to determine the relationship between the stock prices. The analysis screened S&amp;P 500 stocks that show an inverse correlation to Nvidia over a month and year period, following Nvidia&#8217;s <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38177926/whats-next-for-nvidia-as-stock-enters-correction-zone-munster-singles-out-crucial-q">stock falling into correction territory</a> for the second time this month. 
Some technical analysts have suggested that it might be time for investors to offload Nvidia too. Katie Stockton of Fairlead Strategies noted that chart patterns suggest a deeper pullback might be on the horizon "just in time for the seasonal adage of ‘sell in May, and go away' to manifest itself in investor behavior." 
See Also: <a href="https://www.benzinga.com/news/24/04/38286752/elon-musk-reacts-as-marc-andreessen-says-google-is-literally-run-by-employee-mobs-with-chinese-spies?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Reacts As Marc Andreessen Says Google Is &#8216;Literally Run By Employee Mobs&#8217; With &#8216;Chinese Spies&#8217;</a>
Adam Parker of Trivariate Research also listed eight steady growth stocks that could replace Nvidia if investors are worried about overexposure.
Why It Matters: Nvidia&#8217;s stock has been in the spotlight recently. In April, Evercore ISI predicted that <a href="https://www.benzinga.com/markets/equities/24/04/38306414/nvidia-stock-could-see-81-upside-by-2025-says-evercore-isi-only-in-the-beginning-phases-of-gener">Nvidia&#8217;s stock could surge by 81% by 2025</a>, suggesting that the company was only in the initial stages of generating outsized returns. 
However, the stock has been under pressure due to concerns over rising interest rates and a slew of corporate earnings reports. This led to <a href="https://www.benzinga.com/top-stories/24/04/38313015/nvidia-etfs-take-center-stage-as-bears-bulls-duke-it-out-with-8-14-swings">significant swings in Nvidia ETFs</a> as bulls and bears battled it out. 
As of Thursday, Nvidia&#8217;s stock closed at $846.71, marking an increase of 0.76% from the previous close. The stock&#8217;s 52-week high and low are $974 and $262.25 respectively, indicating significant fluctuations in the stock&#8217;s performance.
Read Next: <a href="https://www.benzinga.com/news/24/04/38111017/tesla-ceo-elon-musk-disagrees-with-nvidias-jensen-huang-that-anyone-can-make-their-own-neural-networ?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Tesla CEO Elon Musk Disagrees With Nvidia&#8217;s Jensen Huang That Anyone Can Make Their Own Neural Network: &#8216;It&#8217;s Insanely Hard&#8217;</a>
Photo via Shutterstock
<div style="font-family: 'Lato', sans-serif">
<div>
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>

 Engineered by Benzinga Neuro, Edited by 
 <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Pooja Rajkumari</a> 
 
 
<hr style="border: 0;height: 1px;background: #225aa9" />

 The GPT-4-based Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. 
 <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
 
<hr style="border: 0;height: 5px;background: #225aa9" />
 </div>
</div>

Analyst Color

Tech

General

CTSH

HSIC

NVDA

Jack Daniels Parent Company, EA, Cognizant Among 6 Stocks That Shine When Nvidia Slips: Analysis

Scout Clean Energy (Scout), a Colorado-based renewable energy developer-owner-operator, is pleased to announce they have signed a Virtual Power Purchase Agreement (VPPA) with Zoetis Inc. for a 50-megawatt (MW) portion of Scout's operating Heart of Texas Wind Farm. This constitutes more than one-fourth of the total capacity of the 180 MW project, which produces enough electricity annually to power approximately 67,000 homes.
"We're proud to work with ambitious partners like Zoetis to find creative solutions for renewable procurement," said Michael Rucker, chief executive officer and founder at Scout. "Heart of Texas is an outstanding project and will deliver excellent value to Zoetis as it pursues carbon neutrality."
Heart of Texas, located in McCulloch County, was constructed in 2020 and is owned and operated by Scout, a portfolio company managed by Brookfield Asset Management, a global leader of renewable power and decarbonization solutions. The project supports the local economy through tax incentive agreements with McCulloch County, McCulloch County Hospital District, and Lohn Independent School District.
This VPPA is part of Zoetis' roadmap to achieve carbon neutrality in its own operations by 2030. The 12-year term contract will not only secure renewable energy, but also generate Renewable Energy Certificates (RECs) which will play a role in reducing Zoetis' emissions as part of the RE100 initiative.
"This partnership with Scout Clean Energy reflects our priority to advance sustainability in animal health for a better future," said Jeannette Ferran Astorga, Executive Vice President, Corporate Affairs, Communications and Chief Sustainability Officer at Zoetis. "Through this Virtual Power Purchase Agreement, we are not only securing renewable energy, but also advancing how we can reduce our carbon footprint."

Contracts

Scout Clean Energy Announces 12-Year Virtual Power Purchase Agreement With Zoetis Inc.

Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) has outperformed the market over the past 10 years by 7.37% on an annualized basis producing an average annual return of 17.75%. Currently, Zoetis has a market capitalization of $69.99 billion. 
Buying $1000 In ZTS: If an investor had bought $1000 of ZTS stock 10 years ago, it would be worth $5,276.95 today based on a price of $153.17 for ZTS at the time of writing.
<h3>Zoetis's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713290438_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Zoetis Stock In The Last 10 Years

Piper Sandler analyst David Westenberg reiterates Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) with a Overweight and lowers the price target from $220 to $195.

Reiteration

Piper Sandler Reiterates Overweight on Zoetis, Lowers Price Target to $195

Shares of JPMorgan Chase &amp; Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jpm#NYSE">JPM</a>) fell sharply during Friday&rsquo;s session following first-quarter earnings.
Net revenue (managed) of $42.5 billion (+8% Y/Y), beating the consensus of $41.8 billion. Excluding an item resulted in an increase of $550 million (after tax) to reported net income from $13.4 billion to $14.0 billion and an increase of $0.19 per share to reported EPS from $4.44 to $4.63. EPS was $4.44, beating the consensus of $4.15.
JPMorgan Chase shares dipped 5.1% to $185.49 on Friday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>PaxMedica, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pxmd#NASDAQ">PXMD</a>) jumped 143% to $1.0101 after the company announced the completed execution of its three pivotal registration/validation batches of PAX-101.</li>
<li>EZGO Technologies Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ezgo#NASDAQ">EZGO</a>) gained 83.3% to $2.86. EZGO entered into a $1.84 million procurement agreement for sale of security patrol robots and platform.</li>
<li>Allarity Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/allr#NASDAQ">ALLR</a>) shares jumped 58.8% to $3.6550 after dipping 29% on Thursday. Allarity Therapeutics filed prospectus supplement to increase offering price of common stock that may be offered from $1.4 million to $2.4 million.</li>
<li>Beneficient (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/benf#NASDAQ">BENF</a>) rose 45.5% to $0.1006 after dipping around 10% on Thursday.</li>
<li>NextPlat Corp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nxpl#NASDAQ">NXPL</a>) shares jumped 44% to $2.1799 after the company reported a year-over-year increase in FY23 consolidated revenue results. NextPlat announced a proposed business combination with Progressive Care Inc.</li>
<li>HUB Cyber Security Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hubc#NASDAQ">HUBC</a>) gained 31.6% to $1.54.</li>
<li>9F Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jfu#NASDAQ">JFU</a>) surged 25.1% to $3.63.</li>
<li>Hanryu Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hryu#NASDAQ">HRYU</a>) surged 25% to $0.51.</li>
<li>Argan, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/agx#NYSE">AGX</a>) gained 21.5% to $59.97 as the company reported better-than-expected results for its fourth quarter on Thursday.</li>
<li>Rent the Runway, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rent#NASDAQ">RENT</a>) gained 19.6% to $23.55. Rent the Runway shares jumped 162% on Thursday after the company reported mixed fourth-quarter financial results and issued guidance.</li>
<li>CareMax, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cmax#NASDAQ">CMAX</a>) rose 24% to $3.5751.</li>
<li>Globe Life Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gl#NYSE">GL</a>) climbed 17% to $57.28 amid volatility following a short report on the stock from Fuzzy Panda Research. Globe Life afterwards issued a statement refuting the allegations raised in the report.</li>
<li>Lyell Immunopharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lyel#NASDAQ">LYEL</a>) rose 16.4% to $3.0989.</li>
<li>AMTD Digital Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hkd#NYSE">HKD</a>) shares gained 14.8% to $3.64.</li>
<li>Graphjet Technology (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gti#NASDAQ">GTI</a>) gained 14.6% to $9.93.</li>
<li>Intrusion Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/intz#NASDAQ">INTZ</a>) climbed 13% to $3.09. Intrusion said on Apr. 3, settlement agreement entered by the company on Oct 2, 2023 was approved by court &amp; judgment was entered consistent with settlement agreement.</li>
<li>Gatos Silver, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gato#NYSE">GATO</a>) rose 10.4% to $10.73.</li>
<li>Coupang, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cpng#NYSE">CPNG</a>) gained 10.3% to $21.01 after it was reported the company will raise membership fees.</li>
<li>Mobile-health Network Solutions (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mndr#NASDAQ">MNDR</a>) gained 8.1% to $11.03 on post-IPO volatility.</li>
<li>Nikola Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nkla#NASDAQ">NKLA</a>) rose 4.7% to $0.7503. M&amp;M Residual withdrew its nomination of directors.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Motus GI Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mots#NASDAQ">MOTS</a>) shared dipped 39.7% to $0.2550 after the company announced that it does not believe that it will be able to maintain the listing of its common stock on the Nasdaq and that it does not intend to appeal the staff&#39;s determination. The company said it is exploring a range of strategic and financing alternatives.</li>
<li>Lixiang Education Holding Co., Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lxeh#NASDAQ">LXEH</a>) fell 23.8% to $0.4948.</li>
<li>Monogram Orthopaedics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mgrm#NASDAQ">MGRM</a>) shares declined 22.2% to $3.14. Monogram shares jumped 79% on Thursday after the company announced it joined the NVIDIA Inception program.</li>
<li>C3is Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ciss#NASDAQ">CISS</a>) fell 21.7% to $2.2450.</li>
<li>Sunshine Biopharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sbfm#NASDAQ">SBFM</a>) dipped 19.2% to $0.0703. Sunshine Biopharma announced a 1-for-100 reverse stock split of its common stock, effective at market open on April 17, 2024.</li>
<li>Rallybio Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rlyb#NASDAQ">RLYB</a>) fell 18.1% to $2.44. Rallybio shares jumped around 83% on Thursday after the company announced a collaboration with Johnson &amp; Johnson to advance therapeutics for pregnant individuals at risk of FNAIT..</li>
<li>Marin Software Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrin#NASDAQ">MRIN</a>) fell 16.4% to $0.50. Marin Software shares fell around 8% on Thursday after the company announced upgrades to its integration with Microsoft Advertising.</li>
<li>Destiny Tech100 Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dxyz#NYSE">DXYZ</a>) declined 16.3% to $42.30.</li>
<li>Adial Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adil#NASDAQ">ADIL</a>) shares fell 16.3% to $2.4928. Adial Pharmaceuticals shares jumped 106% on Wednesday after the company announced the publication of a peer-reviewed article highlighting the clinical results, strong safety profile, and high compliance among patients administered AD04.</li>
<li>Agenus Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/agen#NASDAQ">AGEN</a>) declined 15.4% to $7.50. Agenus announced updated Phase 1 data and progress on BOT/BAL development in metastatic MSS colorectal cancer.</li>
<li>Veru Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/veru#NASDAQ">VERU</a>) fell 15% to $1.52.</li>
<li>GCT Semiconductor Holding, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gcts#NYSE">GCTS</a>) fell 12.6% to $6.13.</li>
<li>VIA optronics AG (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/viao#NYSE">VIAO</a>) shares declined 11.5% to $0.3992.</li>
<li>Cassava Sciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sava#NASDAQ">SAVA</a>) fell 11.3% to $23.16.</li>
<li>Sera Prognostics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sera#NASDAQ">SERA</a>) dipped 10.7% to $10.05.</li>
<li>Forge Global Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/frge#NYSE">FRGE</a>) fell 9.1% to $2.0450.</li>
<li>The Lovesac Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/love#NASDAQ">LOVE</a>) declined 8.1% to $19.05. Roth MKM analyst Matt Koranda maintained Lovesac with a Buy and lowered the price target from $34 to $30.</li>
<li>Applied Digital Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/apld#NASDAQ">APLD</a>) fell 7.5% to $2.44 after the company reported worse-than-expected third-quarter financial results.</li>
<li>Zoetis Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/zts#NYSE">ZTS</a>) fell 7.3% to $150.85 following a Wall Street Journal report titled &quot;What Killed Their Pets? Owners Blame Meds, but Vets Aren&#39;t Sure.&quot;</li>
<li>MOGU Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mogu#NYSE">MOGU</a>) fell 7.1% to $1.97 after declining around 8% on Thursday.</li>
<li>Arista Networks, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/anet#NYSE">ANET</a>) declined 6.4% to $277.47 after Rosenblatt downgraded the stock from Buy to Sell.</li>
<li>Nurix Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nrix#NASDAQ">NRIX</a>) fell 5.3% to $16.30 after the company priced its upsized $175 million public offering of 10,166,667 common shares at $15 per share.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/04/38200890/top-3-health-care-stocks-which-could-rescue-your-portfolio-this-quarter"> Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter</a>

Penny Stocks

Small Cap

Intraday Update

ADIL

AGEN

ALLR

ANET

APLD

BENF

CISS

CMAX

CPNG

DXYZ

EZGO

FRGE

GATO

GCTS

HRYU

HUBC

INTZ

LOVE

LXEH

LYEL

MGRM

MNDR

MOGU

MOTS

MRIN

NKLA

NRIX

NXPL

PXMD

RENT

RLYB

SAVA

SBFM

SERA

VERU

VIAO

Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Zoetis Q1 2024 Earnings Preview

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Fortune.com recently reported that artificial intelligence (AI) is helping the pet care industry cope with a chronic veterinary shortage. AI use cases could become <a href="https://fortune.com/2024/04/23/ai-use-cases-health-care-pets-veterinarians/">far more prevalent</a> for pets than humans in the near term due to fewer impediments such as privacy laws. That&rsquo;s excellent news for AI pet stocks.&nbsp;



Indeed, animal health innovation is accelerating in 2024. As an investor, it pays to be aware of trends in this consistently growing industry.&nbsp;The pet sector came into its own during the pandemic. Now post-pandemic, it&rsquo;s faced growing pains as pet owners went back to a more active lifestyle with less time for their animals.&nbsp;



So, who are the companies leading the way in pet care innovation? Among many possibilities, three stand out.



<h2>Zoetis (ZTS)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/02/zts-stock-1-300x169.jpg" alt="Zoetis (ZTS) sign outside the company's headquarters"><div>Source: JHVEPhoto / Shutterstock.com</div></div>Zoetis (NYSE:<a href="https://investorplace.com/stock-quotes/zts-stock-quote/">ZTS</a>) stock is down 21% from its December 52-week high of $201.92 and 18% from its December 2021 all-time high of $247.03. It has lost a lot of ground in the past 40 months.&nbsp;



Fortune.com points out that Zoetis has an AI-powered device to check samples for various diseases and conditions. It&rsquo;s called <a href="https://www.zoetisus.com/products/diagnostics/instruments/vetscan-imagyst">Vetscan Imagyst</a>, and it looks a little like a small microscope. The ZTS website states that it provides &ldquo;a first-of-its-kind technology, offering AI blood smear, AI fecal, and digital cytology image transfer in a single platform.&rdquo;



Providing vets with products that can help them <a href="https://www.dvm360.com/view/ai-powered-diagnostics-providing-individualized-patient-care">diagnose a pet&rsquo;s issues</a> more quickly can be a lifesaver. In a sponsored article for DVM360, Zoetis said the following about its diagnostics product.




&ldquo;The Zoetis Vetscan Imagyst is an in-clinic, multi-use platform that uses deep learning AI and digital microscopy solutions to help diagnose patients within hours or even minutes. Although a practitioner may have a diagnosis in mind, having the technology to back up their opinion can be beneficial.&rdquo;&nbsp;




With <a href="https://www.marketwatch.com/investing/stock/zts/analystestimates">17 of the 19 analysts</a> covering Zoetis stock rating it a buy, with a $224 target price, ZTS looks ready to retest $200 in the next 12-18 months.



<h2>Idexx Laboratories (IDXX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/09/idxx1600-300x169.jpg" alt="vet looking at a dog's xray to represent pet stocks like IDXX"><div>Source: Shutterstock</div></div>Idexx Laboratories (NASDAQ:<a href="https://investorplace.com/stock-quotes/idxx-stock-quote/">IDXX</a>) has a product called IDEXX DecisionIQ that helps vets comb through research, patient histories, online forums and other vital information when assessing the appropriate course of action for <a href="https://www.idexx.com/en/veterinary/software-services/vetconnect-plus/decision-iq/">treating a pet</a>.&nbsp;




&ldquo;DEXX DecisionIQ leverages artificial intelligence with patient-specific data to identify subtle patterns in routine diagnostic testing, allowing for the detection of current or developing disease,&rdquo; <a href="https://www.idexx.com/en/veterinary/software-services/vetconnect-plus/decision-iq/?utm_campaign=DecisionIQ&amp;utm_source=SAH_Facebook&amp;utm_medium=organic_social_post&amp;utm_content=1707248821&amp;fbclid=IwZXh0bgNhZW0CMTEAAR2mjQtpdwjbys52XNwmOzOMRoIsFDRA9VFoiwFFHtVxrWQbSTkyYTJyT18_aem_AfkGDn3JyBEhlSCWtPTCkoxVmZKp8WABqxNliNES8RTw9IIigZH5xe2iHYTPFTm-82qpq3Ft4UpB3-8hKJZ8ec2k#overview">states</a> the company&rsquo;s website.&nbsp;




The website provides a <a href="https://www.idexx.com/files/decision-iq-toby-case-study-en.pdf">case study</a> of a 9-year-old Labrador retriever, Toby, whose face started swelling. The dog&rsquo;s blood work revealed patterns suggesting an increased likelihood of Addison&rsquo;s disease.&nbsp;




&ldquo;Based on the normal electrolytes and reported lack of clinical signs, IDEXX DecisionIQ recommended screening with a resting cortisol to be followed by an ACTH stimulation test if indicated based on the results,&rdquo; stated the case study.&nbsp;




The diagnosis initially led the vet to recommend dental surgery. However, the IDEXX DecisionIQ findings postponed surgery until the dog was healthy enough to receive an anesthetic.&nbsp;



Furthermore, AI innovation will enable Idexx Laboratories to charge more for its products and services in the future.&nbsp;



<h2>Nestle (NSRGY)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/nsrgy-1600-300x169.png" alt="Nestle USA headquarters. NSRGY stock."><div>Source: Ken Wolter / Shutterstock</div></div>Nestle (OTCMKTS:<a href="https://investorplace.com/stock-quotes/nsrgy-stock-quote/">NSRGY</a>) has a market capitalization is about 2.3 times that of Zoetis and Idexx combined. Yet, the Swiss company&rsquo;s pet care business sometimes gets lost in its myriad of operating segments.&nbsp;



The Fortune piece quotes Nestle Purina Petcare North Chief Executive Officer (CEO) Nina Leigh Kruger, who discusses the company&rsquo;s pet health monitoring products.&nbsp;



The <a href="https://www.frog.co/work/petivity-transforms-pet-care-with-ai">Petitivity-connected</a> system sits below a normal litter box and tracks a pet&rsquo;s bathroom behavior. The system uses AI algorithms to understand each cat&rsquo;s unique behavior. Given that cats can be clever at hiding health issues from their pet owners, many consumers would buy this if there weren&rsquo;t any <a href="https://www.petivity.com/products/smart-litter-box-monitor">concerns about price</a>.



Moreover, Petivity is one of many revenue generators for Nestle&rsquo;s pet care division, which accounted for 20% of its 93 billion Swiss francs <a href="https://www.nestle.com/investors/annual-report/facts-figures">($101.24 billion) revenue in 2023</a>. It was the second-highest contributor behind only powdered and liquid beverages such as Nescaf&eacute;, Nespresso, Starbucks and Milo.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;



On the date of publication, Will Ashworth did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.
<div>Will Ashworth has written about investments full-time since 2008. Publications where he&rsquo;s appeared include InvestorPlace, The Motley Fool Canada, Investopedia, Kiplinger, and several others in both the U.S. and Canada. He particularly enjoys creating model portfolios that stand the test of time. He lives in Halifax, Nova Scotia.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/05/furry-tech-boom-3-pet-stocks-unleashing-the-power-of-ai/">Furry Tech Boom: 3 Pet Stocks Unleashing the Power of AI</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Furry Tech Boom: 3 Pet Stocks Unleashing the Power of AI

Phibro Animal Health: An Interesting Deal With Zoetis For A Struggling Business

3 Blue-Chip Bargains Trading At 52-Week Lows

Zoetis Non-GAAP EPS of $1.38 beats by $0.04, revenue of $2.2B beats by $50M

Zoetis gains as Q1 beat addresses concerns over arthritis drug

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Zoetis (NYSE:<a href="https://investorplace.com/stock-quotes/zts-stock-quote/">ZTS</a>) just reported results for the first quarter of 2024.<ul><li>Zoetis reported earnings per share of $1.38. This was above the analyst estimate for EPS of $1.34.</li><li>The company reported revenue of $2.19 billion.</li><li>This was 2.82% better than the analyst estimate for revenue of $2.13 billion.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/zts-stock-earnings-zoetis-for-q1-of-2024/">ZTS Stock Earnings: Zoetis Beats EPS, Beats Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Zoetis Stock (NYSE:ZTS), Short Interest Report

People Also Watch